September 26-28, 2023, Discovery On Target

1) Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion and Therapeutic Resistance
2) Targeting CBP/P300 – Inhibition vs. Degradation for Potent Anti-Tumor Efficacy